Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder

The purpose of this study is to compare the efficacy and safety of SPD417 in treating bipolar manic symptoms, when given once daily in the evening vs. twice daily.

Also known as:

  • A Phase IIIb, Randomized, Double-Blind, Parallel Group Study in Bipolar I Patients to Assess the Efficacy and Safety of SPD417 Administered Once Daily vs Twice Daily in the Treatment of Manic Symptoms

Medical trial

ClinicalTrials.gov Identifier:

  • NCT00150553

Type of trial:

Primary outcomes:

  • Score on Young Mania Rating Scale (YMRS) at 12 weeks

Secondary outcomes:

  • Clinical Global Impressions Scale - Bipolar Version
  • HAM-D and MADRS scales for depression
  • Time to remission

Start date:

  • Jan 2005

End date:

  • Oct 2005

Phase:

Expected total enrollment:

  • 102

Minimum age for eligibility:

  • 18

Eligibility inclusion criteria:

  • DSM-IV criteria for bipolar I disorder
  • Screen YMRS score => 16
  • Women of childbearing potential agree to take adequate precautions against contraception

Eligibility exclusion criteria:

  • History of serious suicide attempt requiring medical intervention
  • Hospitalization required for treatment of psychiatric symptoms
  • Patients who meet DSM-IV for ultra-rapid cycling

Health authority:

Diseases:

Treatment being tested:

top ↑

These people have edited this topic:

Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Freebase Attribution

Freebase data is free for use under the CC-BY license.

Learn more about Freebase licensing and attribution